- Home
- USCB vs ENGN Comparison
USCB vs ENGN Comparison
Compare USCB & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | USCB | ENGN |
|---|---|---|
| Founded | 2002 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.8M | 605.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | USCB | ENGN |
|---|---|---|
| Price | $18.95 | $8.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $22.00 | ★ $22.71 |
| AVG Volume (30 Days) | 48.2K | ★ 236.5K |
| Earning Date | 01-22-2026 | 12-22-2025 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | ★ 50.85 | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $92,331,000.00 | N/A |
| Revenue This Year | $26.31 | N/A |
| Revenue Next Year | $15.23 | N/A |
| P/E Ratio | $12.08 | ★ N/A |
| Revenue Growth | ★ 28.61 | N/A |
| 52 Week Low | $15.39 | $2.65 |
| 52 Week High | $20.49 | $11.14 |
Technical Indicators
Market Signals| Indicator | USCB | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.50 | 50.87 |
| Support Level | $17.83 | $8.17 |
| Resistance Level | $19.38 | $9.81 |
| Average True Range (ATR) | 0.75 | 0.68 |
| MACD | -0.06 | -0.08 |
| Stochastic Oscillator | 47.81 | 39.13 |
Price Performance
Historical ComparisonAbout USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.